

Monument Tx is an independent UK based biotechnology company formed in 2019 as a spin-out from Cambridge Cognition.

Monument Tx develops products to treat serious diseases of the central nervous system. Our precision medicine approach utilises proprietary digital biomarkers to reduce heterogeneity and identify patients with homogenous underlying neurobiology, which are then matched with appropriately targeted compounds.

Using biomarkers to more accurately identify patients with a disease sub-type most likely to respond to a particular treatment is already successfully used in the treatment of cancer. Now Monument Tx brings digital biomarkers to neuroscience drug development to provide a precision medicine approach in clinical areas of high unmet need.

“We want to do for psychiatry and neurology what biomarker testing has done for the diagnosis and treatment of cancer” - The Monument Tx Leadership Team

Monument Tx has a well-balanced pipeline that includes two independent programmes with different and substantial central nervous system indications each with a significant unmet medical need. Proprietary biomarkers developed by the Monument Tx team allows precise selection of the patients most likely to benefit from treatment. The therapeutic products under development are novel formulations utilising generic actives with a known safety profile or will expand the label of approved generics.

The development plan for each programme permits rapid progress with early proof-of-concept data leading to Phase II clinical development.

Therapeutic Area	Programme		Development Status	Trial Phase
Psychiatry	Cognitive Impairment in Schizophrenia	Biomarker	Clinically Validated	Preclinical POC
		Drug	Preclinical Development	
Neurology	Neuroinflammation	Biomarker	Validation Underway	Clinical POC
		Drug	Preclinical Development	